Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

NCT01364688 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-06-02

No results posted yet for this study

Summary

Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

Conditions

  • Vascular Calcification

Interventions

DRUG

oral alfacalcidol

Oral alfacalcidol 0.5 microgram per day

DRUG

no drug

no drug

Sponsors & Collaborators

  • Ramathibodi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01364688 on ClinicalTrials.gov